Early Data Show Promise for Galinpepimut-S and Opdivo in Mesothelioma Patients

galinpepimut-s and opdivo

A combination of the immunotherapy drugs galinpepimut-S and Opdivo may give mesothelioma patients a few extra months, according to newly-released data.  The clinical data is part of an ongoing study of galinpepimut-S and Opdivo. SELLAS Life Sciences Group, the makers of galinpepimut-S, released the latest findings this week.  Although the early data is based on just four mesothelioma cases, it appears to be promising. All of the study subjects had either relapsed after chemotherapy or failed to respond at all.  These patients had a median overall survival of 35.4 weeks on the combination of galinpepimut-S and Opdivo. Typical overall survival in relapsed patients with standard care is just 7 months.  Immunotherapy with Galinpepimut-S and Opdivo Galinpepimut-S and Opdivo are both … Continue reading Early Data Show Promise for Galinpepimut-S and Opdivo in Mesothelioma Patients »

BAP1 Not the Only Gene to Raise Mesothelioma Risk

raise mesothelioma risk

A new study is further evidence that a mutation on the BAP1 gene is not the only genetic anomaly to raise mesothelioma risk. Scientists at Philadelphia’s Fox Chase Cancer Center along with a team of international researchers recently published a study of 13 malignant mesothelioma patients. All of these patients had close relatives who also had cancer. This suggested that something in their genetic makeup might raise mesothelioma risk.  Previous research suggests one gene that makes people more susceptible to mesothelioma is BAP1. People with a mutation on this gene are more likely to receive a mesothelioma diagnosis. They are also more susceptible to several other conditions.  But the people in the new study were chosen because none of them … Continue reading BAP1 Not the Only Gene to Raise Mesothelioma Risk »

Treatment with Vinorelbine for Relapsed Pleural Mesothelioma

treatment with vinorelbine

A new study suggests that treatment with vinorelbine may boost progression free survival for people with relapsed malignant mesothelioma. Mesothelioma is a virulent cancer caused by exposure to asbestos. Chemotherapy is the primary first-line treatment. But this cancer almost always comes back within a few months.  Now, researchers at the UK’s University of Leicester say treatment with vinorelbine might keep mesothelioma at bay for several months longer. They presented their research at this months’ annual meeting of the American Society of Clinical Oncology.  Second-Line Mesothelioma Treatments Needed Pleural mesothelioma is the most common form of mesothelioma. Tumors grow on the membrane around the lungs. The symptoms often mimic lung cancer but can be even more deadly.  Some of the healthiest … Continue reading Treatment with Vinorelbine for Relapsed Pleural Mesothelioma »

Does Pleural Fluid Exposure Affect Mesothelioma Survival?

pleural fluid

A recent study found no link between mesothelioma survival and exposure to pleural fluid. But that does not necessarily mean the link doesn’t exist.  Pleural fluid is also called pleural effusions or “water on the lungs”. It is extra fluid that builds up around the lungs. It is common in people with heart failure, kidney or liver disease, pleural mesothelioma and some other kinds of cancer.  Pleural effusions are usually treated as an uncomfortable mesothelioma symptom. Draining the fluid can help patients breathe easier.  But researchers at Oxford University wondered whether the pleural fluid itself could shorten mesothelioma survival. In this study, the answer appears to be no. But the researchers warn this may not be the final word on … Continue reading Does Pleural Fluid Exposure Affect Mesothelioma Survival? »

Immunotherapy Treatment ONCOS-102: News Keeps Getting Better

immunotherapy treatment

The news just keeps getting better for the virus-based immunotherapy treatment ONCOS-102.  Norweigian drug maker Targovax recently released the final survival data from a two-year study of ONCOS-102 in people with malignant pleural mesothelioma.  Eighteen months into the study, it looked like some of the patients on the immunotherapy treatment would live longer than two years. Now that the ONCOS-102 study has passed the two year mark, researchers say median survival may be even longer.  Average survival is a year or less on standard mesothelioma therapies. This makes the news about ONCOS-102 especially exciting.  Standard of Care Versus Immunotherapy Treatment Malignant mesothelioma is an aggressive malignancy with a poor prognosis. Even patients in overall good health face a grim outlook. … Continue reading Immunotherapy Treatment ONCOS-102: News Keeps Getting Better »

Effectiveness of Keytruda: Dutch Study Offers Clues for Prediction

effectiveness of Keytruda

A new Dutch study offers some clues that might help doctors predict the effectiveness of Keytruda (pembrolizumab) in individual mesothelioma patients.  Keytruda is the brand name for pembrolizumab. It is an immunotherapy drug called an immune checkpoint inhibitor. It helps unmask mesothelioma cells so that the immune system can find and fight them.  But the effectiveness of Keytruda is not consistent. Some patients respond well while others do not respond at all. The new study looked at how different people metabolize the drug. Understanding this could help doctors determine the best dose for each mesothelioma patient.  Pembrolizumab and its Link to Mesothelioma Survival Malignant pleural mesothelioma is a deadly form of lung cancer. Asbestos exposure is the main cause of … Continue reading Effectiveness of Keytruda: Dutch Study Offers Clues for Prediction »

Breath Test Could Predict Mesothelioma Immunotherapy Response

breath test

New research shows a breath test called an eNose might help doctors determine which mesothelioma patients are most likely to respond to immunotherapy.  Immunotherapy is one of the most promising new approaches to malignant mesothelioma. But not every patient responds.  A new Dutch study suggests that biomarkers in a patient’s exhaled breath may be indicators of immunotherapy response. The eNose breath test can identify those biomarkers quickly and easily. The technology might make it easier to decide on the best mesothelioma treatment.  Immunotherapy for Malignant Mesothelioma Pleural mesothelioma is a rare but deadly cancer of the lung lining. Until last year, chemotherapy with Alimta (pemetrexed) was the only FDA-approved systemic treatment.  In 2020, the FDA approved a combination of immunotherapy … Continue reading Breath Test Could Predict Mesothelioma Immunotherapy Response »

Treatment with Dendritic Cells Leads to Long-Term Mesothelioma Survival in Small Studies

dendritic cells

Three small studies suggest that dendritic cells may offer a new, more promising way to fight malignant pleural mesothelioma.  Dendritic cells are immune system cells that function as messengers. They are supposed to signal T-cells to attack cancers like malignant mesothelioma. But mesothelioma cells can keep dendritic cells from doing their job. The result is that the number of activated T-cells around mesothelioma tumors stays low and the tumors keep growing.   Now, Dutch researchers studying the problem say a vaccine made from dendritic cells may hold the answer. They analyzed the results of three small dendritic cell studies. These studies included a total of 29 mesothelioma patients.  Some of the patients in these studies lived much longer than mesothelioma patients normally … Continue reading Treatment with Dendritic Cells Leads to Long-Term Mesothelioma Survival in Small Studies »

Atomic Military Veterans Faced Higher Risk From Asbestos Than Radiation

military veterans

A study published in a US medical journal shows atomic military veterans faced a higher risk from asbestos exposure during their service than they did from radiation.  The study published last summer focused on more than 100,000 veterans. These veterans participated in at least one of 230 above-ground nuclear weapons tests between 1945 and 1962. The tests took place at eight nuclear test sites.  Some soldiers participated in military maneuvers, observed nuclear weapons tests, or provided technical support. Others served on board ships or were stationed on islands during or after nuclear tests.  In spite of their proximity to radioactive weapons, atomic military veterans were more likely to die of an asbestos-related illness like mesothelioma than a radiation-related illness. The … Continue reading Atomic Military Veterans Faced Higher Risk From Asbestos Than Radiation »

Risk of Mesothelioma in Women May be Underestimated

risk of mesothelioma in women

An international team of occupational health experts says science has done a “profound disservice” by underestimating the risk of mesothelioma in women.  Scientists from Germany, Canada, Italy, and the US compiled the report for the American Journal of Industrial Medicine.  They say the risk of mesothelioma in women has long been misunderstood. Asbestos is the main cause of mesothelioma in men. But the new report says studies often fail to link female mesothelioma cases to asbestos exposure.  That omission made some believe that the risk of mesothelioma in women is different than it is in men. But the new report says that is not true. It urges scientists to be more thorough in their mesothelioma studies of women. Asbestos and … Continue reading Risk of Mesothelioma in Women May be Underestimated »

Get your free copy of
“Surviving Mesothelioma” Today!